Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 80
Filter
1.
Br J Anaesth ; 120(4): 645-656, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29576106

ABSTRACT

Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated-as any anticoagulant-with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The objective of this article, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, is to provide an update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure. Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required.


Subject(s)
Anticoagulants/adverse effects , Antithrombins/adverse effects , Emergency Medical Services/methods , Hemorrhage/chemically induced , Hemorrhage/therapy , Administration, Oral , Humans
2.
J Thromb Haemost ; 14(4): 704-15, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26748602

ABSTRACT

BACKGROUND: Antithrombin (AT) is a key regulator of the coagulation. In type II deficiency, the heparin-binding-site defect (type II HBS) is considered to be relatively low thrombosis risk. OBJECTIVES: Our aims were to search for SERPINC1 mutation(s) and to describe the clinical and laboratory phenotype of a large number of AT Budapest3 (ATBp3, p.Leu131Phe) carriers and confirm the presence of a founder effect. PATIENTS/METHODS: AT-deficient patients were recruited and carriers of ATBp3, n = 102 (63 families) were selected. To investigate the founder effect, eight intragenic single nucleotide polymorphisms, a 5'-length dimorphism, and five microsatellite markers were detected. Clinical and laboratory data of the patients were collected and analyzed. RESULTS: In AT deficiency, 16 different causative mutations were found, and the great majority of patients were of type II HBS subtype. Most of them (n = 102/118, 86.5%) carried the ATBp3 mutation. The ATBp3 mutant allele was associated with one single haplotype, while different haplotypes were detected in the case of normal allele. The anti-factor Xa-based AT activity assay that we used could detect all ATBp3 patients with high sensitivity in our cohort. ATBp3 homozygosity (n = 26) was associated with thrombosis at a young age and conferred a high thrombotic risk. Half of the heterozygotes (n = 41/76, 53.9%) also had venous and/or arterial thrombosis, and pregnancy complications were also recorded. CONCLUSION: In Hungary, the founder mutation, ATBp3, is the most common AT deficiency. Our study is the first in which the clinical characterization of ATBp3 mutation was executed in a large population.


Subject(s)
Antithrombins/chemistry , Founder Effect , Heparin/genetics , Leucine/genetics , Mutation , Phenylalanine/genetics , Adolescent , Adult , Aged , Arteries/physiopathology , Binding Sites , Child , Child, Preschool , Cohort Studies , Factor Xa/genetics , Female , Genetic Association Studies , Heterozygote , Humans , Hungary , Microsatellite Repeats , Middle Aged , Phenotype , Polymorphism, Single Nucleotide , Pregnancy , Pregnancy Complications, Cardiovascular , Sensitivity and Specificity , Thrombosis/physiopathology , Young Adult
4.
J Thromb Haemost ; 9(5): 945-52, 2011 May.
Article in English | MEDLINE | ID: mdl-21362127

ABSTRACT

BACKGROUND: Type 3 von Willebrand disease (VWD) is an autosomal recessive bleeding disorder, characterized by virtually undetectable plasma von Willebrand factor (VWF) and consequently reduced plasma factor VIII levels. Genetic mutations responsible for type 3 VWD are very heterogeneous, scattered throughout the VWF gene and show high variability among different populations. METHODS: Twenty-five severe VWD patients were studied by direct sequencing of the 51 coding exons of the VWF gene. The total number of VWD type 3 families in Hungary is 24, of which 23 were investigated. RESULTS: Fifteen novel mutations were identified in 31 alleles, five being nonsense mutations (p.Q1238X, p.Q1898X, p.Q1931X, p.S2505X and p.S2568X), four small deletions and insertions resulting in frame shifts (c.1992insC, c.3622delT, c.5315insGA and c.7333delG), one a large partial deletion (delExon1-3) of the 5'-region, four candidate missense mutations (p.C35R, p.R81G, p.C295S, p.C623T) and one a candidate splice site mutation (c.1730-10C>A). Six previously described mutations were detected in 17 alleles, including the repeatedly found c.2435delC, p.R1659X and p.R1853X. Only one patient developed alloantibodies to VWF, carrying a homozygous c.3622delT. CONCLUSION: We report the genetic background of the entire Hungarian type 3 VWD population. A large novel deletion, most probably due to a founder effect, seems to be unique to Hungarian type 3 VWD patients with high allele frequency. In contrast to previous reports, none of the five patients homozygous for the large partial deletion developed inhibitors to VWF. This discrepancy raises the possibility of selection bias in some of the reports.


Subject(s)
von Willebrand Disease, Type 3/genetics , von Willebrand Factor/genetics , Adolescent , Adult , Child , Female , Gene Deletion , Genotype , Humans , Hungary , Isoantibodies/chemistry , Isoantibodies/genetics , Male , Models, Genetic , Mutation , Mutation, Missense , Registries , Surveys and Questionnaires
5.
J Thromb Haemost ; 8(6): 1273-80, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20088930

ABSTRACT

BACKGROUND: von Willebrand disease (VWD) Vicenza is characterized by low plasma von Willebrand factor (VWF) levels, the presence of ultra-large (UL) VWF multimers and less prominent satellite bands on multimer gels, and the heterozygous amino acid substitution R1205H in the VWF gene. The pathogenesis of VWD Vicenza has been elusive. Accelerated clearance is implicated as a cause of low VWF level. OBJECTIVES: We addressed the question, whether the presence of ultra-large multimers is a cause, or a result of accelerated VWF clearance, or whether it is an unrelated phenomenon. PATIENTS/METHODS: We studied the detailed phenotype of three Hungarian patients with VWD Vicenza, expressed the mutant VWF-R1205H in 293T cells and developed a mathematical model to simulate VWF synthesis and catabolism. RESULTS: We found that the half-life of VWF after DDAVP was approximately one-tenth of that after the administration of Haemate P, a source of exogenous wild-type (WT) VWF (0.81 + or - 0.2 vs. 7.25 + or - 2.38 h). An analysis of recombinant mutant VWF-R1205H showed that the biosynthesis and multimer structure of WT and mutant VWF were indistinguishable. A mathematical model of the complex interplay of VWF synthesis, clearance and cleavage showed that decreasing VWF half-life to one-tenth of normal reproduced all features of VWD Vicenza including low VWF level, ultra-large multimers and a decrease of satellite band intensity. CONCLUSION: We conclude that accelerated clearance alone may explain all features of VWD Vicenza.


Subject(s)
von Willebrand Diseases/metabolism , Amino Acid Substitution , Cell Line , Electrophoresis, Agar Gel , Electrophoresis, Polyacrylamide Gel , Female , Humans , Male , Pedigree , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , von Willebrand Factor/chemistry , von Willebrand Factor/metabolism
6.
J Thromb Haemost ; 1(5): 943-9, 2003 May.
Article in English | MEDLINE | ID: mdl-12871359

ABSTRACT

Development of autoantibody against coagulation factor V (FV) is a rare clinical condition with hemorrhagic complications of varying severity. The aim of this study was to establish the pathomechanism of an acquired FV deficiency and characterize the FV inhibitor responsible for the clinical symptoms. A 78-year-old female was admitted to hospital with severe gastrointestinal bleeding. General clotting tests and determination of clotting factors were performed by standard methods. FV antigen and FV containing immune complexes were measured by ELISA. The FV molecule was investigated by Western blotting and by sequencing the f5 gene. The binding of patient's IgG to FV and activated FV (FVa) was demonstrated in an ELISA system and its effect on the procoagulant activity of FVa was tested in clotting tests and in a chromogenic prothrombinase assay. Localization of the epitope for the antibody was performed by blocking ELISA. FV activity was severely suppressed both in plasma and platelets. FV antigen levels were normal by ELISA using polyclonal anti-FV antibody or monoclonal antibody against the connecting region of FV, but depressed when HV1 monoclonal antibody against the C2 domain in the FV light-chain was used as capture antibody. The FV molecule was found intact. An IgG reacting with both FV and FVa was present in the patient's plasma and its binding to FV was inhibited by HV1 antibody. FV-containing immune complexes were detected in the patient's plasma and platelet lysate. The patient's IgG inhibited the procoagulant function of FVa. An anti-FV IgG was present in the patient's plasma and platelets. The autoantibody reacted with an epitope in the C2 domain of FV light chain and neutralized the procoagulant function of FVa.


Subject(s)
Autoantibodies/blood , Blood Platelets/immunology , Factor V Deficiency/complications , Factor V/immunology , Gastrointestinal Hemorrhage/immunology , Aged , Blood Coagulation Tests , Enzyme-Linked Immunosorbent Assay , Epitopes , Factor V Deficiency/diagnosis , Factor V Deficiency/immunology , Female , Gastrointestinal Hemorrhage/etiology , Humans , Immunoglobulin G/immunology
8.
Thromb Haemost ; 84(1): 88-92, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10928476

ABSTRACT

Von Willebrand's disease (vWD) is the most common congenital haemorrhagic diathesis, characterized by the quantitative or qualitative disorder of von Willebrand factor (vWF). A number of methods have been used for the diagnosis of the disease, and the bleeding time determination is widely accepted as a screening test in spite of its low sensitivity. Our aim was to evaluate and compare the performance of two high shear systems (the O'Brien filter test and the PFA-100 device) in the screening and diagnosis of vWD. Thirty patients (n=13 type 1 with mild symptoms, n = 9 type 1 with severe symptoms, n = 2 type 2A, n = 3 type 2B and n = 3 type 3 vWD) and twenty controls were investigated. In mild vWD the platelet retention in the second phase of the filter test with citrated blood showed the highest sensitivity (91.6%). The sensitivity of the PFA-100 method with collagen-epinephrine cartridges in this group was 76.9%, while the bleeding time was prolonged only in 15.4% of the cases. In severe type 1, in type 2A and type 3 all functional tests reflected the bleeding tendency of the patients. In type 2B disease the bleeding time was prolonged only when the patient was thrombocytopenic, but both high shear systems revealed the disease independently of the presence of thrombocytopenia. The overall sensitivity of the bleeding time determination was 50% compared to the 80-90% sensitivity of the O'Brien filter test and the PFA-100 system. The sensitivity values of the filter test and the PFA-100 device with collagen-epinephrine cartridges were in the same range, but the collagen-ADP cartridges showed a lower (65.5%) sensitivity, though the results were specific and had high positive predictive value. We conclude that both high shear systems are suitable for the screening of vWD, and that they are superior to the traditional bleeding time determination in case of mild disease or type 2B vWD.


Subject(s)
Blood Coagulation Tests/instrumentation , Filtration , Platelet Activation , Platelet Function Tests/instrumentation , von Willebrand Diseases/diagnosis , Adenosine Diphosphate/pharmacology , Adolescent , Adult , Bleeding Time , Collagen/pharmacology , Epinephrine/pharmacology , Female , Humans , Male , Middle Aged , Platelet Activation/drug effects , Sensitivity and Specificity , Stress, Mechanical , von Willebrand Factor/physiology
9.
Platelets ; 11(1): 38-42, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10938880

ABSTRACT

In the differential diagnosis of primary and secondary thrombocytosis platelet function tests may play an important role. We examined the applicability of a platelet filter test (shear-dependent platelet aggregation) as a tool, to differentiate primary thrombocytosis (cases with myeloproliferative disorders) from secondary (reactive) thrombocytosis. The test was carried out in 53 patients suffering from myeloproliferative disorders associated with primary thrombocytosis and in 21 patients with other diseases complicated by secondary thrombocytosis. Using citrate as anticoagulant, the sensitivity of the O'Brien's test proved to be 77.1%, and its specificity 94.4%. Using heparin as anticoagulant the sensitivity and specificity of the test were found to be also reliably high. Based on these studies we suggest the use of the O'Brien's filterometer as a screening test in the differential diagnosis in patients with elevated platelet count. In the case of normal results, the causes of reactive thrombocytosis should be clarified first, while with abnormal results, haematological examination of the patients should be performed.


Subject(s)
Platelet Function Tests/methods , Thrombocytosis/diagnosis , Adenosine Diphosphate/pharmacology , Adult , Aged , Aged, 80 and over , Anticoagulants/pharmacology , Bleeding Time , Chronic Disease , Citric Acid/pharmacology , Diagnosis, Differential , Epinephrine/pharmacology , False Positive Reactions , Female , Filtration , Heparin/pharmacology , Humans , Male , Middle Aged , Myeloproliferative Disorders/blood , Myeloproliferative Disorders/diagnosis , Platelet Activation , Platelet Count , Platelet Function Tests/instrumentation , Sensitivity and Specificity , Thrombocytosis/blood , Thrombocytosis/etiology , von Willebrand Factor/metabolism
10.
Orv Hetil ; 141(41): 2245-50, 2000 Oct 08.
Article in Hungarian | MEDLINE | ID: mdl-11184249

ABSTRACT

Von Willebrand's disease (vWD) is the most common congenital haemorrhagic diathesis, characterized by the quantitative or qualitative disorder of von Willebrand factor (vWF). A number of methods have been used for the diagnosis of the disease, and the bleeding time determination is widely accepted as a screening test in spite of its low sensitivity. Our aim was to evaluate and compare the performance of two high shear systems (the O'Brien filter test and the PFA-100 device) in the screening and diagnosis of vWD. Thirty patients (n = 13 type 1 with mild symptoms, n = 9 type 1 with severe symptoms, n = 2 type 2A, n = 3 type 2B and n = 3 type 3 vWD) and twenty controls were investigated. In mild vWD the platelet retention in the second phase of the filter test with citrated blood showed the highest sensitivity (91.6%). The sensitivity of the PFA-100 method with collagen-epinephrine cartridges in this group was 76.9%, while the bleeding time was prolonged only in 15.4% of the cases. In severe type 1, in type 2A and type 3 all functional tests reflected the bleeding tendency of the patients. In type 2B disease the bleeding time was prolonged only when the patient was thrombocytopenic, but both high shear systems revealed the disease independently of the presence of thrombocytopenia. The overall sensitivity of the bleeding time determination was 50% compared to the 80-90% sensitivity of the O'Brien filter test and the PFA-100 system. The sensitivity values of the filter test and the PFA-100 device with collagen-epinephrine cartridges were in the same range, but the collagen-ADP cartridges showed a lower (65.5%) sensitivity, though the results were specific and had high positive predictive value. We conclude that both high shear systems are suitable for the screening of vWD, and that they are superior to the traditional bleeding time determination in case of mild disease or type 2B vWD.


Subject(s)
Blood Flow Velocity , Hemostatic Techniques , Mass Screening/methods , Platelet Aggregation , von Willebrand Diseases/blood , von Willebrand Diseases/diagnosis , Adult , Bleeding Time , Case-Control Studies , Female , Humans , Male , Middle Aged , Sensitivity and Specificity , Thrombocytopenia/blood , Thrombocytopenia/complications , von Willebrand Diseases/complications , von Willebrand Diseases/prevention & control
11.
Orv Hetil ; 140(30): 1667-71, 1999 Jul 25.
Article in Hungarian | MEDLINE | ID: mdl-10461446

ABSTRACT

Heparin induced thrombocytopenia has remained the major complication of therapy or prophylaxis with heparin. Although low molecular weight heparins seem to confer much lesser chance to induce thrombocytopenia, the danger is still considerable, and the fatal outcome is not rare. A lot of new data have been published about the origin, binding, physicochemical properties of the antibodies, the responsive platelet membrane receptors, and laboratory diagnosis in particular, however, many issues are still unresolved. The anticoagulant treatment of cases, in which heparin induced thrombocytopenia in associated with progressive, frequently arterial thrombosis still needs great skills, experience and the use of new generation antithrombotic agents. This review summarizes briefly the internationally accepted standard diagnostic and therapeutic protocols with heparin induced thrombocytopenia.


Subject(s)
Heparin/therapeutic use , Thrombocytopenia/chemically induced , Thrombosis/drug therapy , Heparin/adverse effects , Humans , Predictive Value of Tests , Prognosis
12.
Thromb Haemost ; 81(5): 668-72, 1999 May.
Article in English | MEDLINE | ID: mdl-10365733

ABSTRACT

Unfractionated heparin (UFH) remains the anticoagulant of choice during pregnancy. Low-molecular-weight heparins (LMWH) are an attractive alternative to UFH due to their logistic advantages and their association with a lower incidence of osteoporosis and HIT. We reviewed all published clinical reports concerning the use of LMWH during pregnancy. In addition, participants of an international interest group contributed a cohort of pregnant women treated with LMWH. Pregnancies were divided into two groups; those with and those without maternal comorbid conditions. The number of adverse fetal outcomes and the occurrence of maternal complications were evaluated in the two groups. In the group of women with comorbid conditions (n = 290), 13.4% of the pregnancies were associated with an adverse fetal outcome. In contrast, in the group of women without comorbid conditions (n = 196), 3.1% were associated with an adverse outcome, which is comparable to that seen in the normal population. We conclude that LMWH appear to be a safe alternative to unfractionated heparin as an anticoagulant during pregnancy.


Subject(s)
Anticoagulants/therapeutic use , Heparin, Low-Molecular-Weight/therapeutic use , Pregnancy Complications, Cardiovascular/drug therapy , Thrombosis/drug therapy , Anticoagulants/administration & dosage , Female , Heparin, Low-Molecular-Weight/administration & dosage , Humans , Pregnancy , Thrombosis/etiology
16.
Haemostasis ; 29(4): 229-36, 1999.
Article in English | MEDLINE | ID: mdl-10702705

ABSTRACT

We describe a patient with positive antinuclear antibodies, polyclonal gammopathy and high level of circulating immunocomplexes, resulting in vascular purpura. In addition, the patient had a slightly prolonged bleeding time and an isolated defect of ristocetin-induced platelet aggregation (RIPA) in platelet-rich plasma (PRP). The patient's plasma also inhibited RIPA in normal PRP and in normal platelet suspension. The activity and multimeric structure of plasmatic von Willebrand factor showed no alteration. We could demonstrate an autoantibody against platelet membrane glycoprotein (GP) Ib, using an ELISA-type assay. These data suggest an acquired Bernard-Soulier syndrome. We suggest that the patient had an immunocomplex-mediated leukocytoclastic vasculitis accompanied by production of antinuclear autoantibodies as well as the presence of an autoantibody against GPIb. The titer of the anti-GPIb antibody, however, was too low to induce significant platelet-type bleeding tendency, only laboratory alterations were found. Moreover, in a later stage of her disease, she developed a severe necrotizing vasculitis which was followed by a deep venous thrombosis.


Subject(s)
Bernard-Soulier Syndrome/complications , Bernard-Soulier Syndrome/immunology , Antibodies, Antinuclear/blood , Antibodies, Antinuclear/pharmacology , Antibodies, Monoclonal/pharmacology , Antigens/blood , Antigens/pharmacology , Autoantibodies/blood , Bleeding Time , Enzyme-Linked Immunosorbent Assay , Female , Humans , Middle Aged , Plasma/drug effects , Plasma/immunology , Platelet Aggregation/drug effects , Platelet Function Tests/instrumentation , Platelet Glycoprotein GPIb-IX Complex/immunology , Polyarteritis Nodosa/immunology , Ristocetin/pharmacology , Venous Thrombosis/immunology , von Willebrand Factor/immunology , von Willebrand Factor/pharmacology
17.
Orv Hetil ; 139(33): 1961-4, 1998 Aug 16.
Article in Hungarian | MEDLINE | ID: mdl-9734213

ABSTRACT

In the differential diagnosis of primary and secondary thrombocytosis, platelet function test can be used. We have examined the possible role of O'Brien's filter test in the differentiation of primary and secondary thrombocytosis in 53 patients with myeloproliferative diseases with primary thrombocytosis and in 21 patients with other disorders complicated by secondary thrombocytosis. By using heparin as an anticoagulant, the sensitivity of O'Brien's filter test proved to be 75%, and it's specificity was 85.7%. In blood samples anticoagulated with citrate, the sensitivity was 100% and specificity 83.3%. Based on these studies we suggest the use of O'Brien's filterometer as a screening test in the differential diagnosis in patients with elevated (> 400 x 10(9)/L) platelet count. In case of normal results, the causes of reactive thrombocytosis should be cleared first, while with pathologic results, haematological examination of the patients should be performed.


Subject(s)
Hemofiltration/methods , Myeloproliferative Disorders/blood , Thrombocytosis/diagnosis , Chronic Disease , Diagnosis, Differential , Humans , Myeloproliferative Disorders/diagnosis , Platelet Function Tests
18.
Orv Hetil ; 139(52): 3113-6, 1998 Dec 27.
Article in Hungarian | MEDLINE | ID: mdl-9914731

ABSTRACT

Thromboembolic complications during pregnancy are the most common causes of maternal death. Here we report on thromboembolic prophylaxis of 60 pregnancies of 32 pregnant women with familial thrombophilia. Long-term Fraxiparine (Sanofi-Chinoin) as thromboprophylaxis was applied in 26 cases throughout pregnancy. UFH (Heparin-Ca inj.) was used in 11 cases, and there were 23 pregnancies without thromboembolic prophylaxis in our patient's case histories. Artificial abortions were not included in this paper. The ratio of successful pregnancies were: with Fraxiparine: 24/26 (92.3%), with UFH (Heparin-Ca): 8/11 (72.7%), without prophylaxis: 4/23 (17.4%). In the patient group treated with Fraxiparine there were no foetopathy, thrombocytopenia or bleeding complication. LMWH is recommended for pregnant women with familial thrombophilia. According to literature data and our own experiences the doses of LMWH in patients with familial thrombophilia, and -antiphospholipid syndrome, and -artificial heart value are suggested.


Subject(s)
Anticoagulants/therapeutic use , Heparin, Low-Molecular-Weight/therapeutic use , Pregnancy Complications, Hematologic/diagnosis , Thrombophilia/diagnosis , Adult , Female , Humans , Maternal Mortality , Nadroparin/therapeutic use , Pregnancy , Pregnancy Complications, Hematologic/drug therapy , Pregnancy Outcome , Thrombophilia/drug therapy , Thrombophilia/genetics
19.
Orv Hetil ; 138(15): 925-9, 1997 Apr 13.
Article in Hungarian | MEDLINE | ID: mdl-9173382

ABSTRACT

Authors studied the effect of coumarin, and its combination with low-dose (125 mg/day) acetylsalicylic acid in the prevention of thromboembolic complication during a 10-year period (average 4.7 years) in a randomized trial of 296 patients aged 18-60 year with tilting disc type prosthetic heart valve (159 mitral and 137 aortic) in sinus rhythm. In the group treated with coumarin (152 patients, 743.4 patient-years) 4 cases (2 of them fatal) of valve thrombosis, 12 cases of peripheral embolism and 9 cases (3 intracranial, 3 among them fatal) of major bleeding were observed; in the group treated with coumarin plus acetylsalicylic acid (144 patients, 638.7 patient-years) 2 cases (1 of them fatal) of valve thrombosis, 4 cases of peripheral embolism and 14 cases (3 of them fatal) of major bleeding were observed. In the case of valve thromboses the difference between the two groups was non-significant but still clinically remarkable; peripheral embolism occurred in significantly higher number (p < 0.05). There was no statistically significant difference of bleeding complications between the two groups. The results suggest that the combination of coumarin plus low-dose acetylsalicylic acid is more effective in the prevention of thromboembolic complications in patients with mitral and aortic prosthetic heart valve than coumarin alone; the danger of bleeding complications seems to be acceptable with adequate control.


Subject(s)
Anticoagulants/administration & dosage , Aspirin/administration & dosage , Coumarins/administration & dosage , Heart Valve Prosthesis , Thromboembolism/prevention & control , Adolescent , Adult , Aged , Aortic Valve/surgery , Female , Heart Valve Prosthesis/adverse effects , Humans , Male , Middle Aged , Mitral Valve/surgery , Thromboembolism/etiology
20.
Orv Hetil ; 138(39): 2455-60, 1997 Sep 28.
Article in Hungarian | MEDLINE | ID: mdl-9380384

ABSTRACT

The atherosclerotic vascular disease is a progressive condition of multifactorial origin. Among cardiovascular risk factors alterations of lipid metabolism are of central role. But the haemostatic system, first of all the plasmatic fibrinogen is also highly implicated. Increased fibrinogen condition can be regarded as a strong and independent predictor of cardiovascular risk. Total cholesterol, LDL-cholesterol and plasma fibrinogen concentration as risk factors are compared. Fibrinogen lowering treatments are also summarized.


Subject(s)
Anticoagulants/administration & dosage , Arteriosclerosis/etiology , Blood Coagulation Factors/analysis , Fibrinogen/analysis , Arteriosclerosis/blood , Arteriosclerosis/prevention & control , Blood Coagulation Factors/antagonists & inhibitors , Cholesterol/blood , Female , Fibrinogen/antagonists & inhibitors , Humans , Hypercholesterolemia/complications , Hyperlipidemias/complications , Hypertension/complications , Lipoproteins/blood , Male , Obesity , Risk Factors , Sex Factors , Smoking/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...